Zura Bio Limited (NASDAQ:ZURA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have received a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $15.80.

Several equities analysts have commented on the stock. HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Chardan Capital decreased their target price on shares of Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Leerink Partnrs raised shares of Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Finally, Leerink Partners began coverage on shares of Zura Bio in a research note on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target on the stock.

Insider Activity

In related news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total transaction of $2,734,458.09. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 22.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zura Bio

Several hedge funds have recently added to or reduced their stakes in ZURA. AQR Capital Management LLC acquired a new stake in Zura Bio during the 2nd quarter worth approximately $43,000. SG Americas Securities LLC acquired a new stake in Zura Bio during the 3rd quarter worth approximately $62,000. Palumbo Wealth Management LLC acquired a new stake in Zura Bio during the 3rd quarter worth approximately $156,000. Charles Schwab Investment Management Inc. boosted its position in Zura Bio by 51.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after buying an additional 98,972 shares during the period. Finally, Valence8 US LP acquired a new stake in Zura Bio during the 3rd quarter worth approximately $71,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

Zura Bio Price Performance

ZURA stock opened at $1.46 on Thursday. Zura Bio has a 12 month low of $1.35 and a 12 month high of $6.35. The company’s 50-day moving average price is $2.00 and its two-hundred day moving average price is $3.18.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.